NEW YORK, Nov. 9 (GenomeWeb News) - Aclara today reported a 34-percent decline in third-quarter revenue as costs for its impending acquisition by ViroLogic helped widen net losses.

 

Total receipts for the three months ended Sept. 30 fell to $181,000 from $276,000 year over year.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.